Dermatology
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.
MD, PhD
Enno Schmidt
Learning objectives
- Recognize the rationale for controlling type 2 inflammation in AD to achieve disease modification, including downstream effects on barrier integrity, microbial dysbiosis, neuronal activation, and pruritus
- Understand that early inflammatory signals can precede clinical onset and support timely intervention
- Describe how earlier, appropriate treatment may reduce cumulative life-course impairment, including long-term psychosocial burden on patients and families
Tags
MAT-GLB-2507496 - 1.0 - 01/2026
About this expert
Dermatology
Enno Schmidt
MD, PhD
Director, Lübeck Institute of Experimental Dermatology Senior Consultant, Department of Dermatology University of Lübeck, Lübeck, Germany
See author’s profile